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Abstract 
Stroke is one of the major causes of death and disability, including ischemic stroke, which 
accounts for 85 - 87 % of cases. Currently, there are few treatment options available for 
minimizing tissue death following a stroke. Emerging data suggest that biomarkers may help 
improve current clinical outcome of stroke. As such, there is a pressing need to understand the 
pathophysiology and to explore effective biomarkers following an ischemic brain event. The 
pathophysiology of ischemic stroke is complex, and majorly involves excitotoxicity, oxidative 
stress, inflammation, blood-brain barrier dysfunction, apoptosis, etc. Several of the biomarkers 
are related to these pathophysiologic mechanisms and they may have applications in stroke 
prediction, diagnosis, assessment, prognosis or treatment. In this review, we summarized the 
pathophysiology of ischemic stroke and some related biomarkers are examined. 
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Stroke is a serious neurological disease and a 
leading cause of disability worldwide [1]. 
Ischemic strokes constitute 85 – 87 % of all 
cases. Hemorrhagic stroke includes 
spontaneous intracerebral hemorrhage and 
subarachnoid hemorrhage, and account for the 
remainder of cases [2].For its enormous clinical, 
social and economic implications, it is urgent to 
understand the mechanisms and thereby 
guiding the diagnosis and therapy of stroke. 
Though neuro-imaging examinations such as 
computed tomography (CT) and magnetic 
resonance imaging (MRI) are excellent in the 
management of stroke patients, biomarkers to 
support a clinical diagnosis of stroke, identify 
patients at risk of disease, and guide treatment 
and prognosis would be valuable [3]. To date, 
many ischemic stroke candidate biomarkers 
have been identified, but none are currently 
used in clinical practice, so further studies and 
researches are demanded. The primary 
objectives of this review are to summarize: (A) 
the pathophysiology of stroke and (B) current 
understanding of biomarkers in stroke. 
 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE 
 
Ischemic cerebrovascular disease is mainly 
caused by thrombosis, embolism and focal 
hypoperfusion, all of which can lead to a 
reduction or an interruption in cerebral blood 
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flow (CBF) that affect neurological function. As 
the brain receives 20% of the cardiac output at 
rest [4], it is exquisitely sensitive to ischemia, 
such that even brief ischemic periods to neurons 
can trigger a complex sequence of events that 
may result in permanent cerebral damage. 
 
Normally, the average CBF in an adult is 
approximately 50 – 55 ml/100g/min [5]. During 
brain ischemia, critically reduced CBF causes 
an inadequate delivery of oxygen and glucose, 
triggering the evolution of stroke 
pathophysiology process. Generally, pathophy-
siology of ischemic stroke can be said to be in 
two stages [5,6]: at a CBF of approximately 
14±2 ml/100 g/min, the electroencephalogram 
becomes isoelectric or evoked responses 
become abnormal, it’s a region of functionally 
impaired but structurally intact tissue, called 
ischemic penumbra and brain damage here is 
reversible; when CBF is reduced to 
approximately 6 ml/100 g/min, the brain damage 
becomes irreversible and results in brain 
infarction, which is called ischemic core. In this 
regard, salvaging of ischemic penumbra is the 
clinical target for acute stroke therapy. 
 
The pathophysiology of stroke is extremely 
complex and involves numerous processes, 
including: energy failure, excitotoxicity, oxidative 
stress, disruption of the blood-brain barrier 




Excitotoxicity refers to a sequence of events 
induced by excessive accumulation of excitatory 
amino acids, leading to toxic increases in 
intracellular calcium [7]. As a second 
messenger, Ca2+ activates multiple signaling 
pathways, which eventually leads to necrosis or 
apoptosis. Soon after reduction or termination of 
CBF, energy-dependent Na+-K+-ATP enzyme is 
inhibited due to reduced ATP production, 
resulting in turbulence of numerous ions, 
including Na+, Cl-, Ca2+. These ions can also be 
interrupted by the overstimulation of 1-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA), kainate and N-methyl-d-aspartic acid 
(NMDA)-type glutamate receptors, all of which 
are receptors of glutamate, a major excitatory 
neurotransmitter in the brain. Then these cells 
become depolarized, which in turn cause more 
Ca2+ influx and more glutamate release. 
Influxing of numerous ions may result in acute 
swelling of cells and additionally, Ca2+ triggers a 
series of events by Ca2+-dependent enemy and 





“Oxidative stress” was first propounded by 
Professor Sohal in 1990. It occurs when there 
is an imbalance between production of free 
radicals and endogenous scavenging capacity 
of cellular antioxidants. Increasing evidence 
suggests that reactive oxygen and nitrogen 
molecules are closely linked to tissue injury 
during acute ischemic stroke [8,9]. Free 
radicals include superoxide anion (O2-), 
hydroxyl radical (OH•), hydrogen peroxide 
(H2O2), nitric oxide (NO) and so on. Among 
which, O2- is generated earliest, while OH• is 
the most toxic. 
 
During ischemic stroke, superoxide anion is the 
primarily generated radical through several 
ways, including mitochondrial electron transport 
process [10], xanthine oxidase (XO) system 
which is thought to be a major source for the 
generation of oxygen free radicals in ischemia 
and reperfusion [11,12], and metabolism of 
arachidonic acid (AA) through the 
cyclooxygenase(COX) pathways. H2O2 is 
formed from superoxide anion and it is the 
source of OH•. NO is generated from L-arginine 
by nitric oxide synthases (NOS) which are 
Ca2+-dependent. NO is very short lived and 
what’s more, it can react with superoxide anion 
to produce peroxynitrite (ONOO-), another 
highly toxic oxygen species [13]. On the other 
hand, antioxidants like superoxide dismutase 
(SOD), glutathione peroxidase (GPX) and 
catalase (CAT) degrade superoxide anion into 
H2O2, additionally transfer H2O2 into H2O. 
Despite these defenses, the brain is vulnerable 
to oxidative stress resulting from ischemia and 
reperfusion. 
 
Oxidative stress is a significant injury during 
cerebral ischemia, these free radicals can 
attack DNA, proteins and lipids [14], increase 
Ca2+, disrupt mitochondrial integrity from which 
Cytochrome C is always released to trigger 
apoptosis, cause varying degrees of damage, 




Several cell types contribute to post-ischemic 
inflammation, including endothelial cells, 
astrocytes, microglia and neurons [15]. The key 
elements in an inflammation reaction involve 
signaling molecules, inflammatory cells, 
adhesion molecules and transcriptional 
regulators. 
 
Increasing amount of Ca2+, oxygen free radical 
and ischemia itself can activate astrocytes and 
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microglia to produce proinflammatory cytokines 
like interleukin-1 (1L-1), tumor necrosis factor-
1(TNF-α) and interleukin-1β (1L-1β), as well as 
neuroprotective factors, such as erythropoietin, 
TGFb1, and metallothionein-2 [16]. Most of 
these cytokines can induce the production of 
some adhesion molecules such as selectins (P-
selectin, E-selectin), immunoglobulin 
superfamily (intercellular adhesion molecule-1, 
vascular endothelial adhesion molecule-1) and 
integrins. Meanwhile interleukin-8 (1L-8), 
monocyte adhesion protein chemistry -1 (MCP-
1) and other chemokines play an important role 
in the migration of inflammatory cells. With the 
help of matrix metalloproteinase (MMP), the 
extracellular matrix is broken down, and 
inflammatory cells infiltrate the brain 
parenchyma. 4-6 h after ischemia onset, 
circulating leukocytes reach the penumbra. 
Neutrophils are thought to be the first leukocyte 
subtypes involved in inflammation [17]. 
 
Blood-brain barrier (BBB) dysfunction 
 
Blood-brain barrier (BBB) disruption in acute 
ischemic stroke varies considerably from15 to 
66 % [18]. Free reactive radicals and 
inflammation are major reasons that contribute 
to the damage of the BBB in acute ischemia 
and reperfusion injury. As important proteases 
in brain tissue, MMPs and serine proteases are 
essential in the breakdown of the extracellular 
matrix around cerebral blood vessels and 
neurons, and their action leads to the 
destruction of BBB, brain edema, hemorrhage, 
and cell death. So, MMPs are thought to be 
direct factors leading to BBB damage [19]. In 
ischemic stroke, besides pro-inflammation 
reaction, free radicals could also affect the 
activities of MMPs both directly and indirectly. 
 
BBB damage is reported to be biphasic in 
ischemic stroke [20]. 2 hours after the onset of 
ischemia, BBB gets a transient opening, which 
may results from oxidative stress that trigger 
activation of MMP-9[21] and MMP-2 [22]. This 
initial opening is followed 1 to 2 days later by a 
second, more severe opening which is more 




There are two forms of cell death, necrosis and 
apoptosis. In ischemic injury, many brain cells 
undergo apoptosis, which in contrast to 
necrosis, is a relatively orderly process that 
allows cells to die with minimal damage and 
disruption to neighboring cells [23]. In this way, 
there is little inflammation or release of genetic 
material [2,24] and they are potentially 
recoverable for some time after the onset of 
stroke.  
 
Caspase-dependent mechanism is important 
for activation of apoptosis. It includes the 
intrinsic pathway, initiated by release of 
cytochrome C from mitochondria and resulted 
in activating caspase-3; and the extrinsic 
pathway, triggered by activation of cell surface 
death receptors and resulted in activating 
caspase-8[25]. Additionally, Caspase-
independent mechanism also plays a vital 
significant role in apoptosis through PARP/AIF 
pathway [25,26]. This is a complex program 
that received much attention in recent years. 
 
BIOMARKERS IN ACUTE ISCHEMIC 
STROKE 
 
In ischemic stroke, ideal biomarkers should 
exhibit characteristics that include sufficient 
specificity and sensitivity, early and stable 
release shortly after infarction, predictable 
clearance, potential for risk assessment and 
guidance of therapies, and the ability to be 
quantitatively and rapidly measured by cost-
effective methodologies [3,27].Many of the 
novel biomarkers of cerebral injury are related 
to the pathophysiology reviewed above, and in 
clinical scenarios, they may have applications 
in stroke prediction, diagnosis, assessment, 




In most cases, the cause of acute ischemic 
stroke is atherothrombosis of large cervical or 
intracranial arteries, or embolism from the heart 
or cerebropetal arteries [28]. In this way, 
molecules involved in coagulation or 
thrombosis are associated with ischemic 
stroke, including fibrinogen, D-dimer and von 
Willebrand factor (vWF), which are most 
reported in recent years. 
 
In terms of risk prediction value, fibrinogen was 
reported both by Fibrinogen Studies 
Collaboration that plasma fibrinogen level was 
significantly associated with coronary heart 
disease (CHD), stroke, and other causes of 
vascular and nonvascular mortality [29], and by 
community-based study in Taiwan that a 72% 
increase (hazard ratio, 1.72; 1.02 to 2.90) in 
ischemic stroke risk was observed for 
individuals with fibrinogen ≥8.79 µmol/L 
compared with those <7.03µmol/L, suggested 
fibrinogen is independently predicted future 
ischemic risk [30]. Also, D-dimer and vWF are 
reported to be associated with increased risk of 
stroke in older men., and these associations 
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were independent of inflammation, especially 
for D-dimer, it is a significant predictor of stroke 
in hypertensive men [31]. 
 
As a novel biomarker for diagnosing stroke, 
vWF can present a high sensitivity and 
specificity when combined with other markers. 
Lynch et al. [32] analyzed twenty-six 
biomarkers with relation to the ischemic 
cascade, from which a panel of four (S100B, 
vWF, MMP9, and VCAM) were able to 
separate ischemic stroke from controls with 
90% sensitivity and specificity. Similarly, 
Laskowitz et al [33] reported a panel of five 
biomarkers (S100B, vWF, MMP9, B-type NGF 
and MCP-1) can diagnose stroke with 92 % 
sensitivity and 93 % specificity. D-dimer can be 
used to distinguish cardioembolic stroke from 
other subtypes of ischemic stroke [34]. When 
D-dimer was combined with D-dimer/fibrinogen 
ratio, CRP and erythrocyte sedimentation, it 
can separate large vessel from cardioembolic 
stroke [35]. Additionally, it is reported that 
plasma D-dimer level on admission is 
significantly related to infarction volume and 
functional outcome in cardioembolic stroke in 
non-valvular atrial fibrillation patients [36]. 
 
Furthermore, Hasan et al [37] found that D-
dimer and fibrinogen have prognostic value with 
the results that D-dimer predicted in-hospital 
death (MD 0.67 µgml-1, 95% CI 0.35, 1.00; p = 
0.0001), and high fibrinogen levels were 
associated with poor outcome at 3 months (MD 
47.90 µgml-1, 95% CI 14.88, 80.93; p = 0.004) 
following ischemic stroke.    
 
Biomarkers in oxidative stress 
 
Since direct measurement of reactive free 
radical (ROS) in the brain is difficult in humans 
because of their transient nature and limitation 
of measurements, endogenous antioxidants as 
well as several biological substances whose 
chemical structure has been modified by free 
radicals have been investigated as potential 




Endogenous antioxidants involve enzymatic 
(CAT, GPX and SOD) and non-enzymatic 
antioxidants (retinol, ascorbic acid, uric acid, α-
tocopherol and carotenoid), all of which 
consists of the cellular protective antiradical 
mechanism. 
 
Antioxidants catalase (CAT) and glutathione 
peroxidase (GPX) can dispose H2O2 in a safe 
way to protect neural cells from oxidative 
stress. Clinical researches showed that CAT 
and GPX activity were significantly higher in 
ischemic patients compared to the controls 
[38,39], and CAT can be considered as 
adequate marker for positive outcome [39]. 
However, others found GPX activity to be 
significantly lower in stroke patients compared 
with controls [40,41]. This debate may result 
from the degree of damage by ROS, since 
antioxidant enzymes might be induced by 
oxidative stress (and therefore their activity 
/levels may increase) or else consumed (thus 
decreasing their activity and levels) [42]. 
 
SOD, the most studied antioxidant enzyme in 
stroke, whose changes of activity/concentration 
in blood were also strongly disputed. Studies 
have found the patients’ SOD activity in plasma 
[39,40], serum [43] and red blood cells [41] to 
be significantly lower than the control group, 
while others found a contrary result of SOD 
activity in red blood cells [44]. Similarly, blood 
concentration of SOD in stroke patients is 
controversial. This debate may because of the 
three different isoforms of superoxide 
dismutase (CuZnSOD, MnSOD and EC-SOD), 
and the different analysis methods [40]. Most 
studies indicate that SOD concentration and 
activity has a significant correlation with 
neurological deficit and infarct size. 
 
Stroke patients have been found to have lower 
levels of retinol, ascorbic acid, uric acid, a-
tocopherol and carotenoids [45,46], but many 
studies have demonstrated some inconsistent or 
negative results [47]. While, despite some 
different result in certain non-enzymatic 
antioxidants, the total antioxidant capacity was 
immediately reduced in acute ischemic stroke 
[48,49]. And some of them have been shown to 
have prognosticating value [48,49]. 
 
Biomarkers of oxidative products 
 
ROS can damage lipids, DNA and proteins. 
Many metabolites produced during these 
processes can be measured in the serum. 
  
Biomarkers of lipid peroxidation 
 
The brain cellular membrane lipids are very rich 
in polyunsaturated fatty acid side chains, which 
are highly prone to free radical attack resulting 
in lipid peroxidation that include biomarkers 
such as malondialdehyde (MDA), thiobarbituric 
acid-reactive substances (TBARs), lipid 
peroxides (ROOH) and F2-isoprostanes(F2IPs). 
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Plasma levels of MDA, TBARs and lipid 
peroxides (ROOH) are commonly used 
biomarkers of oxidative stress. Several studies 
demonstrated that MDA and TBARs levels are 
higher in cerebral ischemia patients than in 
controls, and they are correlated with infarct 
size, clinical stroke severity, and patient’s 
outcome [38,50-54]. However, both MDA and 
TBARs lack specificity for measurement of lipid 
peroxidation, because MDA can not only come 
from lipid peroxidaion products, but also from 
degradation of endoperoxides [42], and what is 
more, when react with TBA, other molecules can 
degradated MDA which increase the amount of 
MDA to react with TBA [55]. 
 
F2IPs are prostaglandin-like products of non-
cyclooxygenase free radical–induced 
peroxidation of arachidonic acid , they are 
thought to be a reliable marker because of its 
good stability, sensitivityand specificity. They 
can be measured in plasma and urine [56]. Kelly 
et al. found that F2IPs plasma levels were 
increased early in ischemic stroke patients 
compared to controls [57]. Nevertheless, there 
are not enough researches about F2IPs. 
 
Biomarkers of DNA oxidation 
 
8-hydroxy-2'-deoxyguanosine (8-OHdG), as a 
product of DNA oxidation, has been widely used 
as an excellent biomarker of oxidative stress 
[58]. An animal study showed that plasma levels 
of 8-OHdG were increased and significantly 
associated with brain content of 8-OHdG [59]. It 
could be useful to identify patients with high risk 
of vascular recurrence or vascular death and to 
identify some particular atherosclerotic plaques 
characteristics [60]. In recent years, 8-OHdG 
has appeared to be a promising molecule, there 
are still more studies needed to determine 
whether it can be a useful peripheral biomarker 
of oxidative damage in stroke patients. 
 
Biomarkers of protein oxidation 
 
There is a lack of studies on biomarkers of 
protein oxidation in ischemic stroke in humans. 
However, a study on patients with Alzheimer’s 
disease and vascular dementia has shown that 
measuring the protein carbonyl and the 
dityrosine contents of immunoglobulins G (IgG) 
can be feasible not only for its increase 
compared to controls [61], but also for its 
sensitivity to dietary antioxidant supplementation 
[62] and a relatively long half-life of 15 days 
which making IgG a good short-term marker of 
oxidative stress [42]. 
Biomarkers of inflammation  
 
Compared to controls, serum levels of IL-1β, IL-
6, IL-8, IL-17, TGF-β, ICAM-1, VCAM-1, E-
selectin, L-selectin, P-selectin, TNF-α, and 
MCP-1 has shown elevation [63-67]. When 
compared to other neurological diseases, serum 
level of IL-6, TNF-α, VCAM-1, BDNF, IL-1β, 
ICAM-1and MMP-2/9 in patients presenting with 
ischemic stroke were found significantly different 
and many of them are correlated with 
neurological deficit and infarct size, such as 
TNF-α, ICAM-1, BDNF and MMP-2/9 [67]. In 
contrast to the findings from other groups 
[68,69], Sotgiu et al found that IL-6 serum level 
showed a significant inverse correlation with 
both final neurological impairment and infarct 
size suggesting that IL-6 is associated with 
neuroprotection rather than neurotoxicity in 
patients with ischemic brain injury [67]. 
 
TNF-α is a major cytokine with a myriad of 
effects. In an inflammatory reaction, It can be 
expressed by endothelial cells, microglia and 
astrocytes, and can induce the expression of 
other molecules. Hosomi et al [70] proved that 
during an ischemia, TNF-α can inhibit the 
production of MMPs and reduce brain edema. 
While, on the contrary, others thought that 
TNF-α activated production of MMPs and 
increases the inflammatory injury [71]. Such 
different results suggest a complex role of TNF-
α in inflammatory mechanisms. 
 
As an important indicator of inflammation, C-
reactive protein (CRP) has been studied 
extensively. It is an acute phase reactant mainly 
produced in liver and rapidly upregulated by 
inflammatory cytokines. Increased levels of 
high-sensitivity C-reactive protein (hsCRP) 
levels have been observed in ischemic stroke 
patients [72]. In ischemic stroke, CRP level are 
correlated with infarct volume and neurological 
deficit, and has potential prognostic value for 
poor outcome [73]. 
 
Central nervous system (CNS) tissue injury 
biomarkers 
 
Ischemic brain injury always cause CNS 
damage, leading to a release of neurons or glia 
specific biomarkers such as acidic calcium-
binding protein (S100β), glial fibrillary acidic 
protein (GFAP), myelin basic protein (MBP), 
neuron-specific enolase (NSE). 
 
Previous studies have agreed that NSE and 
S100β were thought to be of great value for the 
Guo et al 
Trop J Pharm Res, December 2013;12 (6): 
 
1102 
severity of cerebral infarction and prognosis 
estimation in ischemic stroke. Under normal 
circumstances, content of NSE and S100β is 
very low, while when there is an ischemic injury, 
they are released into the cerebrospinal fluid 
(CSF) and the blood through the damaged BBB, 
resulting in an increased levels of NSE and 
S100β [74]. They are closely correlated with 
severity, infarct size and outcome [75,76]. 
 
GFAP is a structural protein that is only present 
in astrocytes, and to a lesser degree, in 
ependymal cells of the brain. It is released when 
cells are disintegrated and the cytoskeletons are 
degraded and its overexpression is specific for 
neurological injury [77]. MBP is a hydrophilic 
protein important for the correct structure of 
myelin sheaths and accounting for about 30% of 
myelin proteins. When the CNS and myelin are 
damaged, GFAP and MBP can be released into 
CSF and blood, and their levels are correlated to 
the degree of injury. They can used to be a 
potential biomarker of CNS injury. 
 
Miscellaneous biomarkers  
 
Nucleoside diphosphate kinase A (NDKA) and 
Parkinson's disease protein 7 (PARK7) are 
recently discovered biomarkers that are closely 
related to ischemic stroke, though their 
mechanism in stroke is not clear. 
Concentrations of NDKA and PARK7 were both 
increased within 3 h of stroke, with sensitivity of 
54 – 91 % for PARK7 and 70 – 90 % for NDKA 
and specificity of 80 – 97 % for PARK7 and 90 – 
97 % for NDKA  suggesting that they can be 
reliable biomarkers for the early diagnosis of 
stroke [78]. When combined GFAP、NDKA and 





The pathophysiological processes following 
acute ischemic stroke are extremely complex. 
Understanding of pathophysiology can help 
improve current clinical conditions of stroke, 
including diagnosis, assessment, prognosis and 
therapy. Meanwhile, biomarkers reflecting 
relevant events in the ischemic cascade would 
also be of great use.  
 
Though a number of blood based biomarkers of 
ischemic stroke have been observed, there  is 
much difficulty in successfully translating this 
advancement to remarkable application in 
clinical practice. Many of them are related to the 
underlying pathophysiology of ischemic stroke. 
The pathogenesis of stroke is complex, involving 
multiple mechanisms, in this way, the detection 
of stroke by use of markers may require multiple 
markers to capture simultaneously all processes 
underlying the ongoing ischemic event [80]. 
Clearly there is much work needed before 
promising biomarker candidates can be 
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